+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Imiquimod does not affect shedding of viable chlamydiae in a murine model of Chlamydia trachomatis genital tract infection



Imiquimod does not affect shedding of viable chlamydiae in a murine model of Chlamydia trachomatis genital tract infection



Infectious Diseases in Obstetrics and Gynecology 11(2): 81-87



Objective: We postulated that either oral or vaginal administration of the immune response modifier imiquimod would decrease vaginal shedding of Chlamydia trachomatis, mouse pneumonitis strain (MoPn), in a murine model. Methods: Female BALB/c mice were infected intravaginally with C. trachomatis (MoPn) and were administered imiquimod either orally (30 mg/kg) or vaginally (10 micro l of 5% imiquimod cream) prior to infection and every second day after infection for a total of four doses.

(PDF emailed within 0-6 h: $19.90)

Accession: 004439607

Download citation: RISBibTeXText

PMID: 14627213

DOI: 10.1080/10647440300025503


Related references

Protective efficacy of a parenterally administered MOMP-derived synthetic oligopeptide vaccine in a murine model of Chlamydia trachomatis genital tract infection: Serum neutralizing IgG antibodies do not protect against chlamydial genital tract infection. Vaccine 13(11): 1023-1032, 1995

The influence of vaginally applied imiquimod on the course of Chlamydia trachomatis genital tract infection. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 41: 456, 2001

Identification of candidate genes using the murine model of female genital tract infection with Chlamydia trachomatis. Drugs of Today 45 Suppl B: 51-59, 2010

Protective efficacy of major outer membrane protein-specific immunoglobulin A (IgA) and IgG monoclonal antibodies in a murine model of Chlamydia trachomatis genital tract infection. Infection and Immunity 63(12): 4704-4714, 1995

The influence of vaginally applied imiquimod on the course of Chlamydia trachomatis serovar D infection in a murine model. Infectious Diseases in Obstetrics and Gynecology 13(1): 1-3, 2005

The Influence of Vaginally Applied Imiquimod on the Course of Chlamydia trachomatis Serovar D Infection in a Murine Model. Infectious Diseases in Obstetrics and Gynecology 13(1): 1-3, 2005

Prior genital tract infection with a murine or human biovar of Chlamydia trachomatis protects mice against heterotypic challenge infection. Infection and Immunity 67(6): 3019-3025, 1999

CD4+ T cells are necessary and sufficient to confer protection against Chlamydia trachomatis infection in the murine upper genital tract. Journal of Immunology 189(5): 2441-2449, 2012

A novel guinea pig model of Chlamydia trachomatis genital tract infection. Vaccine 29(35): 5994-6001, 2011

In situ analysis of the evolution of the primary immune response in murine Chlamydia trachomatis genital tract infection. Infection and Immunity 68(5): 2870-2879, 2000

Sulfated polysaccharides and a synthetic sulfated polymer are potent inhibitors of Chlamydia trachomatis infectivity in vitro but lack protective efficacy in an in vivo murine model of chlamydial genital tract infection. Infection and Immunity 66(3): 1258-1260, 1998

Murine models of Chlamydia trachomatis genital tract infection: use of mouse pneumonitis strain versus human strains. Infection and Immunity 68(12): 7209-7211, 2001

Murine Models of Chlamydia trachomatis Genital Tract Infection: Use of Mouse Pneumonitis Strain versus Human Strains. Infection and Immunity 68(12): 7209-7211, 2000

Effect of Chlamydia trachomatis coinfection on HIV shedding in genital tract secretions. Sexually Transmitted Diseases 28(6): 347-348, 2001

Effect of Chlamydia trachomatis infection and subsequent tumor necrosis factor alpha secretion on apoptosis in the murine genital tract. Infection and Immunity 68(4): 2237-2244, 2000